4.7 Article

Symplocamide A, a potent cytotoxin and chymotrypsin inhibitor from the marine cyanobacterium Symploca sp.

Journal

JOURNAL OF NATURAL PRODUCTS
Volume 71, Issue 1, Pages 22-27

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/np070280x

Keywords

-

Funding

  1. FOGARTY INTERNATIONAL CENTER [U01TW006634] Funding Source: NIH RePORTER
  2. NATIONAL CANCER INSTITUTE [R01CA100851] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053398] Funding Source: NIH RePORTER
  5. FIC NIH HHS [TW006634, U01 TW006634-05, U01 TW006634] Funding Source: Medline
  6. NCI NIH HHS [CA100851, R01 CA100851] Funding Source: Medline
  7. NIEHS NIH HHS [P30 ES00210, P30 ES000210] Funding Source: Medline
  8. NINDS NIH HHS [R01 NS053398-07, NS053398, R01 NS053398] Funding Source: Medline

Ask authors/readers for more resources

Investigation of a Symploca sp. from Papua New Guinea has led to the isolation of symplocamide A (1), a potent cancer cell cytotoxin, which also inhibits serine proteases with a 200-fold greater inhibition of chymotrypsin over trypsin. The complete stereostructure of symplocamide A was determined by detailed NMR and MS analysis as well as chiral HPLC analysis of the component amino acid residues. The presence of several unusual structural features in symplocamide A provides new insights into the pharmacophore model for protease selectivity in this drug class and may underlie the potent cytotoxicity of this compound to H-460 lung cancer cells (IC50 = 40 nM) as well as neuro-2a neuroblastoma cells (IC50 = 29 nM).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available